- Research Letter
- Open Access
Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia
Critical Care volume 24, Article number: 257 (2020)
There were cases of sudden death in some patients infected with COVID-19 including a few of young physicians, which had a huge impact on medical community and society . The unexpected phenomenon lets us think about the underlying problems that caused the sudden death and some issues maybe ignored and that should be appropriately resolved. The initial manifestation of severe COVID-19 pneumonia patients was hypoxemic respiratory failure, accompanied by rapid increased reactive heart rate and susceptibility to supraventricular arrhythmia . It is notable that a proportion of these patients developed sinus bradycardia, which was significantly different from other patients with multiple types of respiratory failure.
In addition to lung injury, cardiac injury has often been reported in patients with COVID-19 . Some experts believed that the virus invasion into myocardium led to severe myocarditis or the severe “cytokine storm”-induced acute myocardial injury may explain the sudden death in some affected patients . It is noteworthy that about 1/3 of the patients with severe illness in our study developed sinus bradycardia (Fig. 1). The troponin and proBNP were basically normal among these patients except for those with renal failure (Table 1). The clinical characteristics of explosive myocarditis and myocardial infarction were not presented among these patients, suggesting these are not the cause of sinus bradycardia in these patients. It was previously reported that no pathological evidence of myocarditis or myocardial microinfarction was observed in the heart of suffered patients , consisting with our results. Therefore, we speculated that sudden death among some severe patients with improved symptoms post-treatment may be caused by severe arrhythmia such as ventricular fibrillation induced by severe sinus delay.
We found that sinus bradycardia often occurred during sleep. So, deep sleep or sedation may be an important risk factor for sinus bradycardia. A few patients had mild to moderate decreased thyroid function, which was consistent with secondary pathological thyroid syndrome and may also be one of the causes of sinus bradycardia. When viral nucleic acid tests gradually turned negative, the heart rate returned to normal no matter whether the patient’s condition improved or worsened and the uses of catecholamine were gradually discontinued. According to the results, we speculated that the inhibitory effect of virus on sinus node activity was the main cause of sinus bradycardia in these patients.
Previous study indicated that COVID-19 invaded host cells via the receptor angiotensin-converting enzyme 2 (ACE2) . Zou et al. identified specific cell types including myocardial cells which were vulnerable to COVID-19 infection through scRNA-seq data analyses . However, there was no severe myocardial damage or cardiac insufficiency in our patients with sinus bradycardia. We referred the gene ontology (GO) enrichment analysis for ACE2 gene in GeneCards Database (https://www.genecards.org/). Biological processes (BP) for ACE2 gene showed that it not only promoted the contraction of cardiac muscle, but also regulated the cardiac conduction. Donoghue et al. demonstrated that cardiac ACE2 overexpression in transgenic mice caused sudden death in a gene dose-dependent fashion; they also found that increased ACE2 expression led to progressive conduction and rhythm disturbances with lethal ventricular arrhythmias via detailed electrophysiology . In light of those evidences, it may be speculated that the toxic role of virus on cardiac conduction system instead of that generated myocardial damage resulted in a sudden death of patients infected with COVID-19.
Taken together, heart rate monitoring of severe COVID-19 pneumonia patients should be strengthened during treatment, and catecholamines should be appropriately applied when necessary. Moreover, a possible inhibitory influence of the virus on activity of cardiac nervous conduction system including sinus node via ACE2 should not be ignored when studying the pathogenic mechanisms among these patients.
Availability of data and materials
The data used to support the findings of this study are available from the corresponding author upon request.
Angiotensin-converting enzyme 2
Creatine kinase isoenzyme
- FiO2 :
High nasal flow oxygen therapy
Severe acute respiratory syndrome coronavirus
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Arabi YM, Fowler R, Hayden FG: Critical care management of adults with community-acquired severe respiratory viral infection. Intens Care Med. 2020;46(2):315–28.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020. https://doi.org/10.1007/s11684-020-0754-0.
Donoghue M. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol. 2003;35(9):1043–53.
The study was financially supported by the National Natural Science Foundation of China (grant/award number: no. 81873420) and the Shanghai Science and Technology Committee (grant/award number: STCSM, nos. 19411969700 and 18411966800). Special fund for clinical research of Zhongshan Hospital, Fudan University, Grant/Award Number: (No. 2016ZSLC11), Sponsor: Lei Zhu.
Ethics approval and consent to participate
Ethical approval for this study was reviewed and approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Shanghai, China).
Consent for publication
The authors declare no conflict of interest. All the authors listed have approved the manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hu, L., Gong, L., Jiang, Z. et al. Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia. Crit Care 24, 257 (2020). https://doi.org/10.1186/s13054-020-02933-3
- Severe pneumonia
- Sinus bradycardia
- Clinical manifestation